<?xml version="1.0" encoding="UTF-8"?>
<p>Teicoplanin is another drug under investigation for COVID-19 infection. This is a glycopeptide antibiotic, currently used in the treatment of Gram-positive bacterial infection, especially in Staphylococcal infections. Already, this antibiotic showed antiviral activity in vitro against viruses, including Ebola, influenza, flavivirus, hepatitis C, HIV, MERS-CoV, and SARS-CoV [
 <xref rid="B72-ijms-21-05145" ref-type="bibr">72</xref>,
 <xref rid="B73-ijms-21-05145" ref-type="bibr">73</xref>,
 <xref rid="B74-ijms-21-05145" ref-type="bibr">74</xref>]. Teicoplanin would act on the early step of genomic viral RNA release and the continuation of SARS-CoV2 life cycle by blocking the low pH cleavage by cathepsin L of the spike protein in the late endosomes [
 <xref rid="B75-ijms-21-05145" ref-type="bibr">75</xref>]. These preliminary results should be confirmed by randomized clinical trials [
 <xref rid="B72-ijms-21-05145" ref-type="bibr">72</xref>].
</p>
